Literature DB >> 8178385

Extracorporeal shock wave lithotripsy for ureteral stones using the Dornier lithotriptor MFL5000.

N Fujimoto1, M Kyo, Y Ichikawa, S Nagano.   

Abstract

A total of 157 ureteral stones in 150 patients were treated by extracorporeal shock wave lithotripsy (ESWL) using the Dornier lithotriptor MFL5000. Stones were treated in situ in 149 cases and with a double-J ureteral stent bypass in 8 cases due to large stone burden or failure of the preceding in situ ESWL. The average number of ESWL sessions and shock waves were 1.6 and 4,446, respectively. Multiple sessions were required in 58 cases (36.9%) for satisfactory fragmentation. At a 3-month follow-up, 91.7% of the cases treated by in situ ESWL and 50% of those treated with a stent bypass were rendered stone-free, achieving an overall stone-free rate of 89.4%. Ureteroscopic extraction or open ureterolithotomy was performed in 4 cases with an impacted stone for the removal of the residual fragments. No serious complications related to ESWL were observed. In situ ESWL is an effective and noninvasive method of treating ureteral stones. Large and/or impacted stones can also be successfully treated by ESWL with or without a stent bypass, but ureteroscopic or surgical procedures may be necessary to salvage fragments packed in the ureteral edema.

Entities:  

Mesh:

Year:  1994        PMID: 8178385     DOI: 10.1159/000282582

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  Assessing the efficiency of extracorporeal shockwave lithotripsy for stones in renal units with impaired function: a prospective controlled study.

Authors:  Anand Srivastava; Tapan Sinha; S C Karan; A S Sandhu; S K Gupta; G S Sethi; R Talwar; V Narang; N Adlakha; A Agarwal
Journal:  Urol Res       Date:  2006-02-15

2.  Complications and outcomes following extracorporeal shock wave lithotripsy: a prospective study of 3,241 patients.

Authors:  Sepehr Salem; Abdolrasoul Mehrsai; Hamed Zartab; Nematollah Shahdadi; Gholamreza Pourmand
Journal:  Urol Res       Date:  2009-12-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.